Cho Eunyoung, Zhang Xuehong, Townsend Mary K, Selhub Jacob, Paul Ligi, Rosner Bernard, Fuchs Charles S, Willett Walter C, Giovannucci Edward L
Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (EC, XZ, MKT, BR, WCW, ELG); Department of Dermatology, The Warren Alpert Medical School of Brown University, Providence, RI (EC); Department of Epidemiology, Brown University School of Public Health, Providence, RI (EC); Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA (JS, LP); Department of Biostatistics (BR), Department of Nutrition (WCW, ELG), and Department of Epidemiology (WCW, ELG), Harvard TH Chan School of Public Health, Boston, MA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA (CSF).
J Natl Cancer Inst. 2015 Sep 15;107(12):djv260. doi: 10.1093/jnci/djv260. Print 2015 Dec.
Higher folate has been associated with a reduced colorectal cancer (CRC) risk, but excessive folate may promote tumor progression. The role of unmetabolized folic acid (UFA) from high folic acid consumption in carcinogenesis is largely unexplored. We evaluated prediagnostic plasma levels of UFA in relation to CRC risk in nested case-control studies (618 CRC case patients and 1207 matched control) with blood samples collected prior to folic acid fortification. UFA was detected in 21.4% of control UFA levels were not associated with CRC risk. Compared with undetectable levels, the multivariable relative risks (RRs) of CRC were 1.03 (95% confidence interval [CI] = 0.73 to 1.46) for less than 0.5 nmol/L and 1.12 (95% CI = 0.81 to 1.55) for 0.5 nmol/L or more (Ptrend = .32). A positive association between UFA levels and CRC risk was observed among men (RR = 1.57, 95% CI = 0.99 to 2.49 for ≥0.5 nmol/L vs undetectable, Pinteraction = .04), and a positive association was also observed among those with the methylene-tetrahydrofolate reductase (MTHFR) CT/TT genotype (RR = 2.20, 95% CI = 1.22 to 3.94 for ≥0.5 nmol/L vs undetectable, Pinteraction=0.02). In conclusion, prediagnostic plasma levels of UFA from the prefortification period were not associated with risk of CRC.
较高的叶酸水平与降低结直肠癌(CRC)风险相关,但过量叶酸可能促进肿瘤进展。高叶酸摄入产生的未代谢叶酸(UFA)在致癌过程中的作用在很大程度上尚未得到探索。在嵌套病例对照研究(618例CRC病例患者和1207例匹配对照)中,我们评估了在叶酸强化之前采集的血样中,诊断前血浆UFA水平与CRC风险的关系。在21.4%的对照中检测到UFA,UFA水平与CRC风险无关。与未检测到的水平相比,CRC的多变量相对风险(RRs)在UFA水平低于0.5 nmol/L时为1.03(95%置信区间[CI]=0.73至1.46),在UFA水平为0.5 nmol/L或更高时为1.12(95%CI=0.81至1.55)(P趋势=.32)。在男性中观察到UFA水平与CRC风险之间存在正相关(对于≥0.5 nmol/L与未检测到的情况,RR=1.57,95%CI=0.99至2.49,P交互作用=.04),在具有亚甲基四氢叶酸还原酶(MTHFR)CT/TT基因型的人群中也观察到正相关(对于≥0.5 nmol/L与未检测到的情况,RR=2.20,95%CI=1.22至3.94,P交互作用=0.02)。总之,强化前时期诊断前血浆UFA水平与CRC风险无关。